CBAY News and Press, CymaBay Therapeutics Inc. From 06/07/22

CymaBay Therapeutics (NASDAQ:CBAY) stock edge higher after disclosing that its CEO Sujal Shah bought 51.301K shares of common stock on 6 June. As per regulatory filing, shares were purchased at $1.95, for total transaction size of $100K. For further details see: CymaBay Therapeutic...

Gainers: Mirati Therapeutics (MRTX) +23%. CymaBay Therapeutics (CBAY) +16%. Veru (VERU) +9%. Kodiak Sciences (KOD) +8%. Allarity Therapeutics (ALLR) +7%. Losers: Verastem (VSTM) -12%. Delcath Systems (DCTH) -11%. Vicarious Surgical (RBOT) -8%. CEL-...

CymaBay Therapeutics (NASDAQ:CBAY -4.3%) said on Monday that results from a new analyses of clinical studies showed that seladelpar treatment through two years resulted in a decrease in Primary Biliary Cholangitis globe score and predicted improved transplant-free survival. The comp...

NEWARK, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from new analyses of cl...

H.C. Wainwright has trimmed the price target on the clinical-stage biopharma company CymaBay Therapeutics (NASDAQ:CBAY) on Monday, citing a delay in the enrollment for the second global Phase 3 trial for its lead candidate seladelpar in primary biliary cholangitis (PBC). With its 1Q 2022 earn...

Image source: The Motley Fool. CymaBay Therapeutics Inc. (NASDAQ: CBAY) Q1 2022 Earnings Call May 12, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: CymaBay Therapeutics Inc. (CBAY) Q1 2022 Earnings Call Transcript...

CymaBay Therapeutics, Inc. (CBAY) Q1 2022 Earnings Conference Call May 12, 2022 16:30 ET Company Participants Paul Quinlan - General Counsel Sujal Shah - Chief Executive Officer Dan Menold - Vice President, Finance Charles McWherter - Chief Scientific Officer Conference Call Participants Stev...

CymaBay Therapeutics press release (NASDAQ:CBAY): Q1 GAAP EPS of -$0.32 misses by $0.01. Held $193.4 million in cash, cash equivalents and investments as of March 31, 2022 For further details see: CymaBay Therapeutics GAAP EPS of -$0.32 misses by $0.01

Over 150 clinical sites now activated in RESPONSE Phase 3 clinical trial Results from a 52-week, open-label phase 2 study of seladelpar in patients with PBC published in the Journal of Hepatology Biopharma leader, Éric Lefebvre , M.D. appointed to the Board ...

NEWARK, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that multiple Phase 2 and Phase 3 st...